{"id":"aqx-1125","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3989954","moleculeType":"Small molecule","molecularWeight":"321.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The NLRP3 inflammasome is a multiprotein complex that plays a key role in the innate immune response. Inhibition of the NLRP3 inflammasome has been shown to reduce inflammation and improve symptoms in various inflammatory diseases.","oneSentence":"AQX-1125 is a small molecule that inhibits the NLRP3 inflammasome.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:53.942Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT03500159","phase":"PHASE2","title":"Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome","status":"TERMINATED","sponsor":"Aquinox Pharmaceuticals (Canada) Inc.","startDate":"2018-04-18","conditions":"Chronic Prostatitis, Chronic Pelvic Pain Syndrome","enrollment":3},{"nctId":"NCT02324972","phase":"PHASE2","title":"Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis","status":"COMPLETED","sponsor":"Aquinox Pharmaceuticals (Canada) Inc.","startDate":"2014-12","conditions":"Atopic Dermatitis","enrollment":54},{"nctId":"NCT03478020","phase":"PHASE1","title":"Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Aquinox Pharmaceuticals (Canada) Inc.","startDate":"2017-11-22","conditions":"Healthy Volunteer","enrollment":32},{"nctId":"NCT02858453","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome","status":"UNKNOWN","sponsor":"Aquinox Pharmaceuticals (Canada) Inc.","startDate":"2016-07","conditions":"Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome","enrollment":433},{"nctId":"NCT01882543","phase":"PHASE2","title":"Efficacy and Safety of AQX-1125 in IC/BPS","status":"COMPLETED","sponsor":"Aquinox Pharmaceuticals (Canada) Inc.","startDate":"2013-06","conditions":"Interstitial Cystitis, Bladder Pain Syndrome","enrollment":69},{"nctId":"NCT03185195","phase":"PHASE1","title":"Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125","status":"COMPLETED","sponsor":"Aquinox Pharmaceuticals (Canada) Inc.","startDate":"2016-11-22","conditions":"Healthy Volunteer","enrollment":9},{"nctId":"NCT01954628","phase":"PHASE2","title":"Efficacy and Safety of AQX-1125 in Unstable COPD","status":"COMPLETED","sponsor":"Aquinox Pharmaceuticals (Canada) Inc.","startDate":"2013-10","conditions":"COPD","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AQX-1125","genericName":"AQX-1125","companyName":"Aquinox Pharmaceuticals (Canada) Inc.","companyId":"aquinox-pharmaceuticals-canada-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AQX-1125 is a small molecule that inhibits the NLRP3 inflammasome. Used for Treatment of rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}